NICE OKs NHS funding for Gilead’s CAR T-cell therapy
Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma.
Read More
Tag: axicabtagene ciloleucel
Gilead strikes deal with NHS England on Yescarta access
Gilead has struck a deal with NHS England that allows some adults with lymphoma access to its “game-changing” CAR-T therapy Yescarta.
Read More
NICE says ‘no’ to Gilead’s Yescarta in draft guidelines
NHS funding for Gilead’s freshly approved CAR-T therapy Yescarta has been turned down in draft guidelines by the National Institute for Health and Care Excellence.
Read More
EU approves first CAR-T therapies
European regulators have approved Novartis’ Kymriah and Gilead’s Yescarta, enabling patients to access CAR-T therapies across the region for the first time.
Read More
CAR-T therapy could be available to NHS patients this year
NHS England chief executive Simon Stevens has indicated that chimeric antigen receptor T-cell therapy (CAR-T) could be available on the NHS this year, offering eligible patients a ‘ground-breaking’ approach to treating cancer.
Read More
US approves second CAR-T therapy
Gilead’s Yescarta – recently acquired through its purchase of Kite Pharma – has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.
Read More
Gilead buys into CAR-T with $11.9bn deal for Kite
Gilead Sciences is buying Kite Pharma in a deal worth $11.9 billion, securing itself access to the latter’s experimental CAR-T therapy axicabtagene ciloleucel and wider cancer pipeline.
Read More
Kite first to submit CAR-T therapy in Europe
Kite Pharma has submitted the first CAR-T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin lymphoma (NHL).
Read More
Novartis gets speedy review for CAR-T cell therapy
Novartis has stepped ahead in the race to get the first cancer-killing CAR-T cell therapy on the market having successfully filed a biologics license application with US regulators.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
